Effects of limiting medicaid drug-reimbursement benefits on the use of psychotropic agents and acute mental health services by patients with schizophrenia.
We examined the effects of a three-prescription monthly payment limit (cap) on the use of psychotropic drugs and acute mental health care by noninstitutionalized patients with schizophrenia.
We hypothesized that reducing access to such drugs would increase the use of emergency mental health services and the rate of partial hospitalizations (full-day or half-day treatment programs) and psychiatric-hospital admissions.
We linked Medicaid claims data for a period of 42 months with clinical records from two community mental health centers (CMHCs) and the single state psychiatric hospital in New Hampshire, where Medicaid imposed a three-prescription limit on reimbursement for drugs during 11 months (months 15 through 25) of the study.
Mots-clés Pascal : Schizophrénie, Indemnité dédommagement, Limite, Psychotrope, Hospitalisation, Hôpital psychiatrique, Chimiothérapie, Coût, Epidémiologie, Homme
Mots-clés Pascal anglais : Schizophrenia, Indemnity, Limit, Psychotropic, Hospitalization, Psychiatric hospital, Chemotherapy, Costs, Epidemiology, Human
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 94-0668319
Code Inist : 002B18C06A. Création : 09/06/1995.